Te Arai Rare Disorders Medicines recommended for PHARMAC funding

June 6 2019

The February 2019 meeting of the Pharmacology and Therapeutics Advisory Committee (PTAC) included review of the November 2018 Rare Disorders Subcommittee meeting recommendations to fund 4 new Medicines. During its meeting PTAC accepted the high priority recommendations to fund two Te Arai BioFarma products – Carglumic acid (for the treatment of metabolic disorders CPS1 and NAGs) […]

Read More

Te Arai Rare Disorders Medicines recommended for PHARMAC funding

February 20 2019

The PHARMAC Rare Disorders Subcommittee met November 5 and 6 2018 to consider the funding of Medicines for the treatment of Rare Disorders. Rare Disorders are defined as those affecting less than 1 in 50,000 New Zealanders, often these Medicines are referred to a Orphan Medicines. The subcommittee can recommend a Medicine is funded, decline […]

Read More

New recommendation for PHARMAC to fund sapropterin for PKU patients

January 30 2019

The Medicine sapropterin has been recommended to be funded by PHARMACs Pharmacology and Therapeutics Advisory Committee (PTAC). Sapropterin is a treatment for a rare metabolic condition phenylketonuria (PKU), which is one of the disorders screened for at birth.  PKU results in an inability for the body to process the amino acid phenylalanine causing accumulation. Phenylalanine is […]

Read More

New Medicine Sapropterin Registered

May 24 2018

The Te Arai BioFarma pharmaceutical product sapropterin has been registered by Medsafe for supply to New Zealanders. Registration occurred during international PKU awareness month.   Sapropterin has been designated as an orphan drug for treating the rare metabolic condition phenylketonuria (PKU). PKU leads to an abnormally high concentration of the amino acid phenylalanine (Phe) in […]

Read More

New Zealand is a step closer to funding the cardiovascular polypill

January 31 2018

The pharmaceutical buying agency PHARMAC has received a positive recommendation to fund Trinomia, a combination of aspirin (a blood ‘thinning’ agent to reduce blood clots), atorvastin (to reduce harmful cholesterol levels) and ramipril (to reduce blood pressure) for New Zealanders.   PHARMACs cardiovascular subcommittee, mainly specialist cardiologists, provides clinical advice for PHARMAC. The committee has recommended […]

Read More

Microdacyn leads new Wound Care Review

July 31 2017

A new evidence review for the prevention of infection and wound management have recently been released. The review is accompanied by training modules supported by The Accident Compensation Corporation (ACC). The relatively high incidence of wound infection in New Zealand coupled with reduced health outcomes have prompted its release. Microdacyn Wound Care Solution and Hydrogel […]

Read More

Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications

April 10 2017

New Zealand research has demonstrated that a cardiovascular polypill can improve adherence to medicines proven to improve survival. Medicines are only effective if we take them although in New Zealand only a fraction of people that have suffered a cardiovascular event (heart attack or stroke) take the medicines proven to make them live longer. This […]

Read More

World Health Organisation considers Trinomia® as an Essential Medicine

March 13 2017

Trinomia®,the first cardiovascular polypill, is being considered by the WHO as an Essential Medicine.   Inclusion on the Essential Medicines List (EML) allow access and funding for poor, lower and middle income countries. Supporters of the application including institutes such as Oxford University, the University of Auckland, Harvard Medical School and the World Heart Federation […]

Read More

Microdacyn Leads The Way In New International Guidelines

January 15 2017

Microdacyn wound care solution has been included in the new International Wound Infection Institute (IWII) clinical practice Guidelines.   The IWII is a multidisciplinary international group of experts dedicated to sharing the latest developments in wound infection and infection prevention. The guidelines have a focus on biofilm and wound infection.   Microdacyn is newly included […]

Read More

UroFem receives ACC Listing

September 30 2016

UroFem 1000mg d-mannose tablets are now a listed medical consumable, meaning UroFem is funded for relevant people eligible under Accident Compensation Corporation (ACC).   Urinary Tract Infections (UTIs) affect a large number of people that have received an accident related injury, including trauma and burns. People most affected include those with a spinal cord injury […]

Read More

Older posts